(Albany, US) DelveInsight launched a new report on Critical Limb Ischemia Market Insights, Epidemiology and Market Forecast-2030
DelveInsight’s “Critical Limb Ischemia – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Critical Limb Ischemia , historical and forecasted epidemiology as well as the Critical Limb Ischemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the report
- The prevalence of Critical Limb Ischemia is 12% in the adult population.
- Critical Limb Ischemia account for only between 1% and 3% of all patients with PAD, with an incidence of between 500 and 1000 per million persons per year in Europe and North America.
- It is estimated that there are approximately 2 million total Critical Limb Ischemia patients in the United States.
Key benefits of the report
1. Critical Limb Ischemia market report covers a descriptive overview and comprehensive insight of the Critical Limb Ischemia epidemiology and Critical Limb Ischemia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Critical Limb Ischemia market report provides insights into the current and emerging therapies.
3. Critical Limb Ischemia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Critical Limb Ischemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Critical Limb Ischemia market.
Request for sample pages : https://www.delveinsight.com/sample-request/critical-limb-ischemia-market
” According to Delveinsight, males are affected more as compared to females, in case of Critical Limb Ischemia.”
Critical Limb Ischemia (CLI) is a severe obstruction of the arteries which markedly reduces blood flow to the extremities (hands, feet, and legs) and has progressed to the point of severe pain and even skin ulcers or sores. The pain caused by CLI can wake up an individual at night. This pain, also called “rest pain”, is often in the leg and can be relieved temporarily by hanging the leg over the bed or getting up to walk around.
CLI is a very severe condition of peripheral artery disease (PAD) and needs comprehensive treatment by a vascular surgeon or vascular specialist. It is the advanced stage of peripheral artery disease (PAD), which results from a progressive thickening of an artery’s lining (caused by a buildup of plaque). This buildup of plaque, also known as atherosclerosis, narrows or blocks blood flow, reducing circulation of blood to the legs, feet, or hands.
The risk factors for critical limb ischemia include Age (Men over 60 and women after menopause),
Smoking, Diabetes, Overweight or obesity, High cholesterol, High blood pressure.
The launch of the emerging therapies is expected to significantly impact Critical Limb Ischemia treatment scenario in the upcoming years:-
Drugs covered:
- AAV-hTERT
- ACP-01
- PLX-PAD
- CLBS12
And many others
The key players in Critical Limb Ischemia market are:
- Libella Gene Therapeutics
- Hemostemix
- Pluristem
- Caladrius Biosciences
And many others
Request for sample pages : https://www.delveinsight.com/sample-request/critical-limb-ischemia-market
Table of contents
1. Report Introduction
2. Executive Summary
3. SWOT Analysis
4. Critical Limb Ischemia Market Overview at a Glance
4.1. 7 Major Market Size of Critical Limb Ischemia in 2017
4.2. 7 Major Market Size of Critical Limb Ischemia in 2030
5. Disease Background and Overview: Critical Limb Ischemia
5.1. Introduction
5.2. Causes
5.3. Pathophysiology
5.4. Symptoms
5.5. Risk Factor
5.6. Diagnosis
6. Epidemiology and Patient Population
6.1. Assumptions and Rationale
6.2. 7MM Prevalent cases of Critical Limb Ischemia (2017–2030)
6.3. 7MM Grade-specific Prevalence of Critical Limb Ischemia (2017–2030)
6.4. 7MM Age-specific Prevalence of Critical Limb Ischemia (2017–2030)
6.5. 7MM Gender-specific Prevalence of Critical Limb Ischemia (2017–2030)
6.6. 7MM Diagnosed and Treatable Cases of Critical Limb Ischemia (2017–2030)
7. Critical Limb Ischemia: Country- Wise Epidemiology
7.1. United States
7.1.1. Prevalent cases of Critical Limb Ischemia in the United States (2017–2030)
7.1.2. Grade-specific Prevalence of Critical Limb Ischemia in the United States (2017–2030)
7.1.3. Age-specific Prevalence of Critical Limb Ischemia (2017–2030)
7.1.4. Gender-specific Prevalence of Critical Limb Ischemia in the United States (2017–2030)
7.1.5. Diagnosed and Treatable Cases of Critical Limb Ischemia in the United States (2017–2030)
7.2. EU-5
7.2.1. Germany
7.2.1.1. Prevalent cases of Critical Limb Ischemia in Germany (2017–2030)
7.2.1.2. Grade-specific Prevalence of Critical Limb Ischemia in Germany (2017–2030)
7.2.1.3. Age-specific Prevalence of Critical Limb Ischemia in Germany (2017–2030)
7.2.1.4. Gender-specific Prevalence of Critical Limb Ischemia in Germany (2017–2030)
7.2.1.5. Diagnosed and Treatable Cases of Critical Limb Ischemia in Germany (2017–2030)
7.2.2. France
7.2.2.1. Prevalent cases of Critical Limb Ischemia in France (2017–2030)
7.2.2.2. Grade-specific Prevalenceof Critical Limb Ischemia in France (2017–2030)
7.2.2.3. Age-specific Prevalence of Critical Limb Ischemia in France (2017–2030)
7.2.2.4. Gender-specific Prevalence of Critical Limb Ischemia in France (2017–2030)
7.2.2.5. Diagnosed and Treatable Cases of Critical Limb Ischemia in France (2017–2030)
7.2.3. Italy
7.2.3.1. Prevalent cases of Critical Limb Ischemia in Italy (2017–2030)
7.2.3.2. Grade-specific Prevalence of Critical Limb Ischemia in Italy (2017–2030)
7.2.3.3. Age-specific Prevalence of Critical Limb Ischemia in Italy (2017–2030)
7.2.3.4. Gender-specific Prevalence of Critical Limb Ischemia in Italy (2017–2030)
7.2.3.5. Diagnosed and Treatable Cases of Critical Limb Ischemia in Italy (2017–2030)
7.2.4. Spain
7.2.4.1. Prevalent cases of Critical Limb Ischemia in Spain (2017–2030)
7.2.4.2. Grade-specific Prevalence of Critical Limb Ischemia in Spain (2017–2030)
7.2.4.3. Age-specific Prevalence of Critical Limb Ischemia in Spain (2017–2030)
7.2.4.4. Gender-specific Prevalence of Critical Limb Ischemia in Spain (2017–2030)
7.2.4.5. Diagnosed an Treatable Cases of Critical Limb Ischemia in Spain (2017–2030)
7.2.5. United Kingdom
7.2.5.1. Prevalent cases of Critical Limb Ischemia in the United Kingdom (2017–2030)
7.2.5.2. Grade-specific Prevalence of Critical Limb Ischemia in the United Kingdom (2017–2030)
7.2.5.3. Age-specific Prevalence of Critical Limb Ischemia in the United Kingdom (2017–2030)
7.2.5.4. Gender-specific Prevalence of Critical Limb Ischemia in the United Kingdom (2017–2030)
7.2.5.5. Diagnosed and Treatable Cases of Critical Limb Ischemia in Spain (2017–2030)
7.3. Japan
7.3.1. Prevalent cases of Critical Limb Ischemia in Japan (2017–2030)
7.3.2. Grade-specific Prevalence of Critical Limb Ischemia in Japan (2017–2030)
7.3.3. Age-specific Prevalence of Critical Limb Ischemia in Japan (2017–2030)
7.3.4. Gender-specific Prevalence of Critical Limb Ischemia in Japan (2017–2030)
7.3.5. Diagnosed and Treatable Cases of Critical Limb Ischemia in Spain (2017–2030)
8. Treatment & Medical Practices
8.1. Treatment Algorithm
8.2. Treatment Guidelines
9. Patient Journey
10. Key Emerging Therapies
10.1. AAV-hTERT: Libella Gene Therapeutics
10.1.1. Regulatory Milestones
10.1.2. Clinical Development
10.1.3. Product Profile
10.1.4. Clinical Pipeline Activity
10.1.5. Ongoing Trials Information
10.1.6. Clinical Trial by Phase
10.2. ACP-01: Hemostemix
10.2.1. Regulatory Milestones
10.2.2. Clinical Development
10.2.3. Product Profile
10.2.4. Clinical Pipeline Activity
10.2.5. Ongoing Trials Information
10.2.6. Clinical Trial by Phase
To be continued in the report………
11. Attribute Analysis
12. Critical Limb Ischemia: Market Size
12.1. Key Findings
12.2. Total 7MM Critical Limb Ischemia Market Analysis
12.2.1. Overview of Total Critical Limb Ischemia Market
12.2.2. Market size of Critical Limb Ischemia by 7MM (2017–2030)
13. 7MM Critical Limb Ischemia: Country-Wise Market Analysis
13.1. United States
13.1.1. Total Market Size of Critical Limb Ischemia
13.1.2. Market Size of Critical Limb Ischemia by Therapies
13.2. Germany
13.2.1. Total Market Size of Critical Limb Ischemia
13.2.2. Market Size of Critical Limb Ischemia by Therapies
13.3. France
13.3.1. Total Market Size of Critical Limb Ischemia
13.3.2. Market Size of Critical Limb Ischemia by Therapies
13.4. United Kingdom
13.4.1. Total Market Size of Critical Limb Ischemia
13.4.2. Market Size of Critical Limb Ischemia by Therapies
13.5. Spain
13.5.1. Total Market Size of Critical Limb Ischemia
13.5.2. Market Size of Critical Limb Ischemia by Therapies
13.6. Italy
13.6.1. Total Market Size of Critical Limb Ischemia
13.6.2. Market Size of Critical Limb Ischemia by Therapies
13.7. Japan
13.7.1. Total Market Size of Critical Limb Ischemia
13.7.2. Market Size of Critical Limb Ischemia by Therapies
14. Market Access and Reimbursement
15. Market Drivers
16. Market Barriers
17. Appendix
18. Report Methodology
18.1. Sources Used
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Critical Limb Ischemia – Pipeline Insights, 2020
The Critical Limb Ischemia report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Critical Limb Ischemia across the complete product development cycle, including all clinical and nonclinical stages.
Critical Limb Ischemia – Epidemiology Forecast to 2030
The Critical Limb Ischemia epidemiology covered in the report provides historical as well as forecasted Critical Limb Ischemia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/